The efficacy and adverse effect of intralymphatic immunotherapy (ILIT) for allergic diseases

Not Applicable

Terminated

• Conditions: Diseases of th respiratory system

• Registration Number: KCT0001534
• Lead Sponsor: Gachon University Gil Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Terminated
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

Allergic rhinitis to house dust mite (Df, Dp), cat or dog
- More than 3mm reaction at skin prick test for Df, Dp, cat or dog
or more than class 3 at serum specific IgE level (ImmunoCAP® or multiple allergosorbent test)

Exclusion Criteria

- Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA) guideline
- FEV1 less than 50% of predicted value if there is comorbid asthma.
- Subject rejects the enrollment into study
- Low compliance
- Pregnancy or lactation
- Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious diseases
- Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic antidepressant, immnosuppressant including systemic glucocorticosteroid (20mg or more dose of prednisolone or equivalent dose of other steroid) within last 2 weeks
- Prior history of allergen-specific immunotherapy
- Allergic rhinitis caused by other perennial or seasonal allergen
- Vulnerable volunteer

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rhinoconjunctivitis quality of life questionnaire (RQLQ)

Secondary Outcome Measures

Name	Time	Method
Sino-Nasal outcome Test (SNOT-20);Allergen wheal diameter in skin prick test and intradermal test;cut-off point of concentration in nasal provocation test for D. farinae and D. pteronyssinus;Serum allergen specific IgE level;Levels of IL-4, IFN-g, and IL-10 cytokines in nasal lavage fluid